ClinicalTrials.gg
CompletedNCT02239120Updated Sep 6, 2019Results posted

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

A Phase 3 interventional study of optional ASA as comedication and placebo to ASA in Stroke and Secondary Prevention, sponsored by Boehringer Ingelheim. Completed at 569 sites in 42 countries. Open to participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,390
Allocation
Randomized
Ages
18 Years to 150 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Stroke by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Stroke · Boehringer Ingelheim.

Enrollment
3rd of 12
5,390 · median 686
Started
2014
the only one that year
Phase 3
7 of 23
none open now
Registered
15th of 23
by date

Among the 23 studies in Stroke by Boehringer Ingelheim, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2014, is one of 7 in phase 3, and was the 15th registered.

Stroke

8,277 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

None of the 23 studies in Stroke by Boehringer Ingelheim is open now. The open studies under Stroke, anywhere →

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 150 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Stroke by Boehringer Ingelheim as a file.
02

Study summary

This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).

03

Conditions studied

  • Stroke
  • Secondary Prevention

Browse trials for

04

Who can participate

Ages eligible
18 Years to 150 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ischemic stroke with a brain lesion visualized by neuroimaging (either brain Computed Tomography (CT) or Magnetic Resonance Image (MRI)). The visualized stroke is a non-lacunar infarct , e.g. involving the cortex or >1.5 cm (>2.0 cm if measured on MRI diffusion-weighted images) in largest diameter if exclusively subcortical.Visualization by CT usually requires delayed imaging >24-48 hours after stroke onset.
  • The index stroke must have occurred either up to 3 months before randomization (Modified Rankin Scale(mRS) \<=3 at randomization) or up to 6 months before randomization (mRS \<=3 at randomization) in selected patients that are >= 60 years plus at least one additional risk factor for recurrent stroke.
  • Arterial imaging or cervical plus Transcranial Doppler (TCD) ultrasonography does not show extra-cranial or intracranial atherosclerosis with >= 50% luminal stenosis in artery supplying the area of acute ischemia.
  • As evidenced by cardiac monitoring for >= 20 hours with automated rhythm detection, there is absence of AF > 6 minutes in duration (within a 20 hour period, either as single episode or cumulative time of multiple episodes).

Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  • Modified Rankin Scale of >=4 at time of randomization or inability to swallow medications.
  • Major risk cardioembolic source of embolism such as: a) intracardiac thrombus as evidenced by transthoracic or transesophageal echocardiography, b) paroxysmal, persistent or permanent Atrial fibrillation (AF), c) atrial flutter, d) prosthetic cardiac valve (mitral or aortic, bioprosthetic or mechanical), e) atrial myxoma, f) other cardiac tumors, g) moderate or severe mitral stenosis, h) recent (\< 4weeks) myocardial infarction, i) valvular vegetations, or j) infective endocarditis.
  • Any indication that requires treatment with an anticoagulant as per Investigator's judgment.
  • History of atrial fibrillation (unless it was due to reversible causes such as hyperthyroidism or binge drinking, and has been permanently resolved).
  • Other specific stroke etiology (i.e. cerebral arteritis or arterial dissection, migraine with aura/vasospasm, drug abuse).
  • Renal impairment with estimated (as calculated by Cockcroft-Gault equation) \<30mL/min at screening, or where Investigator expects creatinine clearance is likely to drop below 30mL/min during the course of the study.

Further exclusion criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
5,390 participants (actual)

Study arms

  • Experimental
    dabigatran etexilate 110 or 150 mg

    Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)

    Drug: optional ASA as comedication · Drug: placebo to ASA · Drug: dabigatran etexilate

  • Active comparator
    ASA 100 mg

    All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d

    Drug: placebo to optional ASA as comedication · Drug: placebo to dabigatran etexilate · Drug: ASA 100 mg

Interventions

  • Drugoptional ASA as comedication

    optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.

  • Drugplacebo to ASA

    placebo to comparator drug

  • Drugplacebo to optional ASA as comedication

    optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.

  • Drugplacebo to dabigatran etexilate

    placebo

  • active comparator drug

  • active drug

06

What researchers measure

Primary outcomes

  1. Adjudicated Recurrent Stroke

    Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period.

    Time frame: From randomisation until full follow up period, approximately 43 months.

  2. First Major Bleed (Adjudicated)

    First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or, * Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or, * Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period.

    Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

Secondary outcomes

  1. Adjudicated Ischaemic Stroke

    Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period.

    Time frame: From randomisation until full follow up period, up to 43 months

  2. Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death

    Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period.

    Time frame: From randomisation until full follow up period, up to 43 months

  3. Disabling Stroke

    Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period.

    Time frame: From randomisation until full follow up period, up to 43 months

  4. All-cause Death

    All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period.

    Time frame: From randomisation until full follow up period, up to 43 months

  5. Adjudicated Intracranial Hemorrhage

    Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic. The annualised event rate represents the average number of events per patient during a 1-year period.

    Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

  6. Adjudicated Fatal Bleed

    Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated.

    Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

  7. Adjudicated Life-threatening Bleed

    Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention. The annualised event rate represents the average number of events per patient during a 1-year period.

    Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

  8. Any Bleed (Investigator-reported)

    This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity. The annualised event rate represents the average number of events per patient during a 1-year period.

    Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

07

Results

Posted Sep 6, 2019

Participant flow

This was randomised, active comparator, double-blind, 2 arms (1:1 ratio) event-driven Phase III trial in participants with embolic stroke of undetermined source (ESUS). Study was conducted at multiple centers in 42 countries between 3 Dec 2014 (first participant enrollment) and 14 August 2018 (last participant visit).

Participant flow — Overall Study
MilestoneDabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Started26952695
Completed26202623
Not completed7572
Withdrew: Death5658
Withdrew: Lost to follow-up1914

Outcome measures

PrimaryAdjudicated Recurrent Stroke

Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period.

Time frame:
From randomisation until full follow up period, approximately 43 months.
Reported as:
Number · Annualised event rate (%/ year)
Adjudicated Recurrent Stroke
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Adjudicated Recurrent Stroke4.094.80
Statistical analysis
  • Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg · Regression, Cox · p = 0.1028 · Hazard ratio (hr): 0.85 · 95% CI 0.69 to 1.03Covariates in model are age(\<or\>= 75years), creatinine clearance \< or \>= 50mL/min and stroke or transient ischaemic attack(TIA) prior to index stroke.
PrimaryFirst Major Bleed (Adjudicated)

First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or, * Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or, * Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period.

Time frame:
Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Reported as:
Number · Annualised event rate (%/ year)
First Major Bleed (Adjudicated)
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
First Major Bleed (Adjudicated)1.841.33
Statistical analysis
  • Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg · Regression, Cox · p = 0.1076 · Hazard ratio (hr): 1.36 · 95% CI 0.94 to 1.97Covariates in model are age(\<or\>= 75years), creatinine clearance \< or \>= 50mL/min and stroke or transient ischaemic attack(TIA) prior to index stroke.
SecondaryAdjudicated Ischaemic Stroke

Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period.

Time frame:
From randomisation until full follow up period, up to 43 months
Reported as:
Number · Annualised event rate (%/ year)
Adjudicated Ischaemic Stroke
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Adjudicated Ischaemic Stroke3.974.71
Statistical analysis
  • Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg · Regression, Cox · p = 0.0892 · Hazard ratio (hr): 0.84 · 95% CI 0.68 to 1.03Covariates in model are age(\<or\>= 75years), creatinine clearance \< or \>= 50mL/min and stroke or transient ischaemic attack(TIA) prior to index stroke.
SecondaryAdjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death

Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period.

Time frame:
From randomisation until full follow up period, up to 43 months
Reported as:
Number · Annualised event rate (%/ year)
Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death4.805.40
Statistical analysis
  • Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg · Regression, Cox · p = 0.1911 · Hazard ratio (hr): 0.88 · 95% CI 0.73 to 1.06Covariates in model are age(\<or\>= 75years), creatinine clearance \< or \>= 50mL/min and stroke or transient ischaemic attack(TIA) prior to index stroke.
SecondaryDisabling Stroke

Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period.

Time frame:
From randomisation until full follow up period, up to 43 months
Reported as:
Number · Annualised event rate (%/ year)
Disabling Stroke
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Disabling Stroke0.550.93
Statistical analysis
  • Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg · Regression, Cox · p = 0.0354 · Hazard ratio (hr): 0.59 · 95% CI 0.36 to 0.96Covariates in model are age(\<or\>= 75years), creatinine clearance \< or \>= 50mL/min and stroke or transient ischaemic attack(TIA) prior to index stroke.
SecondaryAll-cause Death

All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period.

Time frame:
From randomisation until full follow up period, up to 43 months
Reported as:
Number · Annualised event rate (%/ year)
All-cause Death
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
All-cause Death1.241.28
Statistical analysis
  • Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg · Regression, Cox · p = 0.8074 · Hazard ratio (hr): 0.96 · 95% CI 0.66 to 1.38Covariates in model are age(\<or\>= 75years), creatinine clearance \< or \>= 50mL/min and stroke or transient ischaemic attack(TIA) prior to index stroke.
SecondaryAdjudicated Intracranial Hemorrhage

Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic. The annualised event rate represents the average number of events per patient during a 1-year period.

Time frame:
Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Reported as:
Number · Annualised event rate (%/ year)
Adjudicated Intracranial Hemorrhage
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Adjudicated Intracranial Hemorrhage0.670.63
Statistical analysis
  • Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg · Regression, Cox · p = 0.9064 · Hazard ratio (hr): 1.03 · 95% CI 0.58 to 1.83Covariates in model are age(\<or\>= 75years), creatinine clearance \< or \>= 50mL/min and stroke or transient ischaemic attack(TIA) prior to index stroke.
SecondaryAdjudicated Fatal Bleed

Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated.

Time frame:
Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Reported as:
Number · Annualised event rate (%/ year)
Adjudicated Fatal Bleed
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Adjudicated Fatal Bleed0.000.05
SecondaryAdjudicated Life-threatening Bleed

Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention. The annualised event rate represents the average number of events per patient during a 1-year period.

Time frame:
Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Reported as:
Number · Annualised event rate (%/ year)
Adjudicated Life-threatening Bleed
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Adjudicated Life-threatening Bleed0.760.91
Statistical analysis
  • Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg · Regression, Cox · p = 0.4352 · Hazard ratio (hr): 0.82 · 95% CI 0.49 to 1.36Covariates in model are age(\<or\>= 75years), creatinine clearance \< or \>= 50mL/min and stroke or transient ischaemic attack(TIA) prior to index stroke.
SecondaryAny Bleed (Investigator-reported)

This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity. The annualised event rate represents the average number of events per patient during a 1-year period.

Time frame:
Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Reported as:
Number · Annualised event rate (%/ year)
Any Bleed (Investigator-reported)
Annualised event rate (%/ year)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Any Bleed (Investigator-reported)15.2111.64
Statistical analysis
  • Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg · Regression, Cox · p = 0.0003 · Hazard ratio (hr): 1.28 · 95% CI 1.12 to 1.47Covariates in model are age(\<or\>= 75years), creatinine clearance \< or \>= 50mL/min and stroke or transient ischaemic attack(TIA) prior to index stroke.

Adverse events

Collected over Adverse Events (AE) and serious AE starting between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months. All-cause mortality reported from randomisation until full follow up period, approximately 43 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate 110 or 150 Milligram (mg)56/2,695 (2.1%)724/2,676 (27.1%)306/2,676 (11.4%)
Acetylsalicylic Acid, Aspirin (ASA) 100 mg58/2,695 (2.2%)740/2,674 (27.7%)295/2,674 (11%)
Most frequent serious events
Showing 10 of 640
Most frequent serious events
EventDabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
Cerebrovascular accidentNervous system disorders95/267697/2674
Ischaemic strokeNervous system disorders47/267645/2674
Transient ischaemic attackNervous system disorders46/267641/2674
Cerebral infarctionNervous system disorders25/267642/2674
Atrial fibrillation or atrial flutterCardiac disorders34/267629/2674
EpilepsyNervous system disorders18/267625/2674
Atrial fibrillationCardiac disorders24/267620/2674
FallInjury, poisoning and procedural complications21/26769/2674
OsteoarthritisMusculoskeletal and connective tissue disorders12/267619/2674
PneumoniaInfections and infestations18/267614/2674
Most frequent other events
Most frequent other events
EventDabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mg
NasopharyngitisInfections and infestations173/2676170/2674
Atrial fibrillationCardiac disorders136/2676128/2674

Baseline characteristics

Randomised set (RS): The RS consisted of all patients who were randomised, regardless of whether they took trial medication. The start date of the observation period for this population was the date of randomisation.

Age, Continuous
Age, Continuous(Years)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mgTotal
Mean64.5 ± 11.4463.9 ± 11.3964.2 ± 11.42
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mgTotal
Female10019861987
Male169417093403
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mgTotal
Hispanic or Latino281268549
Not Hispanic or Latino235423714725
Unknown or Not Reported6056116
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dabigatran Etexilate 110 or 150 Milligram (mg)Acetylsalicylic Acid, Aspirin (ASA) 100 mgTotal
American Indian or Alaska Native112031
Asian6315971228
Native Hawaiian or Other Pacific Islander246
Black or African American544094
White192619663892
More than one race101222
Unknown or Not Reported6156117
08

Study locations

569 sites
  • Bronislava Shafran, MD PC
    Phoenix, Arizona 85006, United States
  • Westside Medical Associates of Los Angeles
    Beverly Hills, California 90211, United States
  • TriWest Research Associates, LLC
    El Cajon, California 92020, United States
  • University of California
    Fresno, California 93721, United States
  • Glendale Adventist Medical Center
    Glendale, California 91206, United States
  • Collaborative Neuroscience Network, LLC (CNS)
    Long Beach, California 90806, United States
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Huntington Hospital
    Pasadena, California 91105, United States
  • University of California
    San Diego, California 92103, United States
  • University of California
    San Francisco, California 94143, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Colorado Neurological Institute
    Englewood, Colorado 80113, United States
  • University of Colorado Denver
    Fort Collins, Colorado 80528, United States
  • St. Mary's Hospital and Regional Medical Center
    Grand Junction, Colorado 81501, United States
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • JEM Research Institute
    Atlantis, Florida 33462, United States
  • Boca Raton Regional Hospital
    Boca Raton, Florida 33486, United States
  • Tenet Florida Physician Services
    Boynton Beach, Florida 33472, United States
  • Nova Clinical Research, LLC
    Bradenton, Florida 34209, United States
  • Broward Health North
    Deerfield Beach, Florida 33064, United States
  • Center for Advanced Research Excellence
    Hialeah, Florida 33016, United States
  • Bruce W. Carter, Miami VA Healthcare System
    Miami, Florida 33125, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Bay Neurological Institute
    Panama City, Florida 32405, United States
  • Carol L Pappas, MD PhD PA
    Saint Petersburg, Florida 33713, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Vero Beach Neurology and Research Institute
    Vero Beach, Florida 32960, United States
  • Palm Beach Neuroscience Institute
    West Palm Beach, Florida 33409, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • WellStar Medical Group - Neurosurgery
    Marietta, Georgia 30060, United States
  • The Queen's Medical Center
    Honolulu, Hawaii 96813, United States
  • Saint Alphonsus Medical Center-Neurology
    Boise, Idaho 83704, United States
  • Northwest Heart Clinical Research, LLC
    Arlington Heights, Illinois 60005, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Medicoricium, LLC
    Fairview Heights, Illinois 62208, United States
  • OSF Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • Quincy Physicians and Surgeons Clinic, S.C.
    Quincy, Illinois 62301, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Community Clinical Research Center
    Anderson, Indiana 46011, United States
  • Ruan Neurology Clinic and Research Center
    Des Moines, Iowa 50314, United States
  • Associates in Neurology, PSC
    Lexington, Kentucky 40513, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana 71301, United States
  • Culicchia Neurological Clinic
    Marrero, Louisiana 70072, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • Anne Arundel Medical Center
    Annapolis, Maryland 21401, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Newton-Wellesley Hospital
    Newton, Massachusetts 02462, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • McLaren Flint
    Flint, Michigan 48532, United States
  • Mercy Health Saint Mary's
    Grand Rapids, Michigan 49503, United States
  • Spectrum Health Medical Center
    Grand Rapids, Michigan 49503, United States
  • Sparrow Clinical Research Institute
    Lansing, Michigan 48912, United States
  • St. Joseph Mercy Oakland
    Pontiac, Michigan 48341, United States
  • The Duluth Clinic dba Essentia Health Duluth Clinic
    Duluth, Minnesota 55805, United States
  • Abbott Northwestern Hospital, Radiology Department
    Minneapolis, Minnesota 55407, United States
  • HealthPartners Neuroscience Center
    Saint Paul, Minnesota 55130, United States
  • Jackson Heart Clinic, P.A.
    Jackson, Mississippi 39216, United States
  • Boone Hospital Center
    Columbia, Missouri 65201, United States
  • University of Missouri Health System
    Columbia, Missouri 65201, United States
  • SSM Health St. Clare Hospital
    Fenton, Missouri 63026, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Saint Louis University
    Saint Louis, Missouri 63104, United States
  • St. Louis Heart and Vascular, P.C.
    Saint Louis, Missouri 63136, United States
  • The Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Renown Institute for Neurosciences
    Reno, Nevada 89502, United States
  • NYC Health + Hospitals/Coney Island
    Brooklyn, New York 11235, United States
  • New York Presbyterian Hudson Valley Hospital
    Cortlandt Manor, New York 10567, United States
  • UHS Wilson Medical Center,Office of Clin Trials
    Johnson City, New York 13790, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Mount Sinai Beth Israel
    New York, New York 10003, United States
  • Novant Health Neurology Specialists
    Charlotte, North Carolina 28207, United States
  • Duke Clinic 1L
    Durham, North Carolina 27710, United States
  • Cone Health System
    Greensboro, North Carolina 27401, United States
  • Novant Health Neurology Hickory
    Hickory, North Carolina 28602, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Altru Health System
    Grand Forks, North Dakota 58201, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Holzer Clinic LLC
    Gallipolis, Ohio 45631, United States
  • Advanced Neurology Associates
    Youngstown, Ohio 44504, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97239, United States
  • Veterans Affairs Portland Health Care System
    Portland, Oregon 97239, United States
  • Sacred Heart Medical Center at RiverBend
    Springfield, Oregon 97477, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Abington Neurological Associates
    Willow Grove, Pennsylvania 19090, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Greenville Memorial Hospital
    Greenville, South Carolina 29605, United States
  • Methodist University Hospital
    Memphis, Tennessee 38105, United States
  • Centennial Heart Cardiovascular Consultants, LLC
    Nashville, Tennessee 37203, United States
  • Saint Thomas Health
    Nashville, Tennessee 37205, United States
  • Seton Medical Center Austin
    Austin, Texas 78705, United States

Showing the first 100 of 569 sites across 42 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Del Brutto VJ, Diener HC, Easton JD, Granger CB, Cronin L, Kleine E, Grauer C, Brueckmann M, Toyoda K, Schellinger PD, Lyrer P, Molina CA, Chutinet A, Bladin CF, Estol CJ, Sacco RL. Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial. J Am Heart Assoc. 2022 Jun 7;11(11):e023545. doi: 10.1161/JAHA.121.023545. Epub 2022 Jun 3. PubMed 35656979 ↗
  • Diener HC, Easton JD, Hart RG, Kasner S, Kamel H, Ntaios G. Review and update of the concept of embolic stroke of undetermined source. Nat Rev Neurol. 2022 Aug;18(8):455-465. doi: 10.1038/s41582-022-00663-4. Epub 2022 May 10. PubMed 35538232 ↗
  • Bahit MC, Sacco RL, Easton JD, Meyerhoff J, Cronin L, Kleine E, Grauer C, Brueckmann M, Diener HC, Lopes RD, Brainin M, Lyrer P, Wachter R, Segura T, Granger CB; RE-SPECT ESUS Steering Committee and Investigators. Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. Circulation. 2021 Nov 30;144(22):1738-1746. doi: 10.1161/CIRCULATIONAHA.121.055176. Epub 2021 Oct 15. PubMed 34649459 ↗
  • Uchiyama S, Toyoda K, Lee BC, Liou CW, Wong LKS, Grauer C, Brueckmann M, Taniguchi A, Urano Y, Easton JD; RE-SPECT ESUS Investigators. Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis. Stroke. 2021 Mar;52(3):1069-1073. doi: 10.1161/STROKEAHA.120.031891. Epub 2021 Feb 16. PubMed 33588594 ↗
  • Diener HC, Chutinet A, Easton JD, Granger CB, Kleine E, Marquardt L, Meyerhoff J, Zini A, Sacco RL. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. Stroke. 2021 Mar;52(3):1065-1068. doi: 10.1161/STROKEAHA.120.031237. Epub 2021 Jan 28. PubMed 33504190 ↗
  • Diener HC, Sacco RL, Easton JD, Granger CB, Bar M, Bernstein RA, Brainin M, Brueckmann M, Cronin L, Donnan G, Gdovinova Z, Grauer C, Kleine E, Kleinig TJ, Lyrer P, Martins S, Meyerhoff J, Milling T, Pfeilschifter W, Poli S, Reif M, Rose DZ, Sanak D, Schabitz WR. Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups. Stroke. 2020 Jun;51(6):1758-1765. doi: 10.1161/STROKEAHA.119.028643. Epub 2020 May 14. PubMed 32404035 ↗
  • Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M, Donnan G, Ferro JM, Grond M, Kallmunzer B, Krupinski J, Lee BC, Lemmens R, Masjuan J, Odinak M, Saver JL, Schellinger PD, Toni D, Toyoda K; RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019 May 16;380(20):1906-1917. doi: 10.1056/NEJMoa1813959. PubMed 31091372 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Aug 2018, 44 months.

Results were first posted in Sep 2019, 1 year after primary completion.

Of 37 industry-sponsored phase 3 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's 44 months is close to that.

Counting every sponsor, half of 129 studies reached it within 44 months; a quarter within 27 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2014
First posted
Sep 12, 2014
StartActual
Nov 27, 2014
Primary completionActual
Aug 14, 2018
CompletionActual
Aug 14, 2018
Results first posted
Sep 6, 2019
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02239120
Responsible party
Sponsor
First posted
Sep 12, 2014
Start date
Nov 27, 2014
Primary completion
Aug 14, 2018
Completion
Aug 14, 2018
Results posted
Sep 6, 2019
Last update
Sep 6, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion